| Literature DB >> 19689824 |
Martin Schencking1, Adriane Otto, Tobias Deutsch, Hagen Sandholzer.
Abstract
BACKGROUND: The increasing age of the population, especially in the western world, means that the prevalence of osteoarthritis is also increasing, with corresponding socioeconomic consequences. Although there is no curative intervention at present, in accordance with US and European guidelines, pharmacotherapeutic and non-pharmacological approaches aim at pain control and the reduction of functional restriction.It has been established that hydrotherapy for osteoarthritis of the hip or knee joint using serial cold and warm water stimulation not only improves the range of movement but also reduces pain significantly and increases quality of life over a period of up to three months. Weight reduction is important for patients with osteoarthritis of the hip or knee. In addition, conventional physiotherapy and exercise therapy have both been shown, at a high level of evidence, to be cost-effective and to have long-term benefits for pain relief, movement in the affected joint, and patient quality of life. METHODS/Entities:
Mesh:
Year: 2009 PMID: 19689824 PMCID: PMC2736923 DOI: 10.1186/1471-2474-10-104
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Figure 1Alternate thigh affusion according to Kneipp – flow direction (repeated cold/warm water stimulation). The thigh affusion is poured starting from the back of the foot up the outer aspect of the back of the leg, slowly over the buttocks ("starting away from the heart going towards the heart"), from there moving to the front aspect of the leg, lingering in the groin, and finally pouring the water over the inner aspect of the leg downwards.
Eligibility criteria
| 1 | Age ≥ 18 years |
| 2 | Symptomatic osteoarthritis of hip or knee (following the revised criteria of the American College of Rheumatology) |
| 3 | Willingness to comply with follow-up assessments and treatment |
| 4 | Ability to understand, read and speak German |
| 1 | Endoprothetic replacement of hip or knee joint |
| 2 | Inflammatory arthropathy of the hip or the knee |
| 3 | Acute, hot, red and swollen knee or hip joint (unknown focus) |
| 4 | Inflammatory system diseases which could interfere with the evaluation of the therapy procedure |
| 5 | CNS diseases, especially epilepsy |
| 6 | Anamnesis of deep vein thrombosis in the past 12 months |
| 7 | Severe lung disease such as e.g. COPD stages GOLD III – GOLD IV |
| 8 | Heart failure NYHA III – NYHA IV |
| 9 | Myocardial ischemia with or without intervention within the last 3 months before inpatient admission |
| 10 | Cancer in advanced stage |
| 11 | Large skin wounds or inflammatory and ulcerated dermatosis of the legs |
| 12 | Severe febrile infectious diseases Non treated hypertension |
| 13 | Participation in another clinical study within the past four weeks |
| 14 | Pregnancy |
Figure 2Flowchart describing the participant flow through the study. Diagramm over the participant flow through recruitment, randomization, baseline measurement, post-treatment and 3 month follow-up.
Figure 3Schedule of data acquisition. [pq = physicians questionnaire]. EQ-5D = EuroQol questionnaire; AIMS2-SF = Arthritis Impact Measurement Scale.